Decitabine
Acute Myeloblastic Leukemia With Maturation
Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Roswell Park Cancer Institute
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02029417CT.gov Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Terminated | — | — | — |
NCT01607645CT.gov Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS | — | Terminated | — | — | — |
NCT02085408CT.gov Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Acute Myeloblastic Leukemia With Maturation
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Decitabine (this asset) | Roswell Park Cancer Institute | P3 | BB · 66 |
| Etoposide | Stanford University | P3 | BBB |
| Cytarabine | Northwestern University | P3 | BBB |
| Daunomycin | National Cancer Institute (NCI) | P3 | BBB |
| Cyclophosphamide | ECOG-ACRIN Cancer Research Group | P3 | BB |
| Idarubicin | Bruno C. Medeiros | P3 | BB |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P2 | BB |
| Nivestim | Rutgers, The State University of New Jersey | P3 | BB |
| Mitoxantrone | Stanford University | P2 | BB |
+41 more in the Acute Myeloblastic Leukemia With Maturation cohort
Other indications for Decitabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia | — | P4 | BB · 69 |
| Disease Related To Hematopoietic Stem Cell Transplant | — | P4 | BB · 68 |
| Acute Myeloid Leukemia With T(8;21)(Q22;Q22) Translocation | — | P3 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Decitabine in Acute Myeloblastic Leukemia With Maturation. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/decitabine-acute-myeloblastic-leukemia-with-maturation
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →